Novo Nordisk: study results for hemophilia A

(CercleFinance.com) - Novo Nordisk has announced the top-line results of the FRONTIER 2 trial.


The Frontier 2 trial shows that Mim8 administered once weekly and once monthly provides a superior reduction in treated bleeding episodes compared with on-demand treatment and prior prophylaxis in people with hemophilia A.

The trial met its co-primary endpoints by demonstrating a statistically significant and superior reduction in bleeding episodes treated with Mim8 once weekly and once monthly compared to no prophylaxis and prior clotting factor prophylaxis.

'We are very pleased with the positive results of the FRONTIER 2 clinical trial. These data demonstrate the ability of Mim8 to effectively and safely prevent bleeding episodes in people with hemophilia A, regardless of the frequency of administration', said Martin Holst Lange, Executive Vice President Development at Novo Nordisk.

Depending on regulatory interactions, Novo Nordisk aims to submit Mim8 for first regulatory approval towards the end of 2024. Data from the FRONTIER Phase 3 program, including FRONTIER 2, will be disclosed at upcoming congresses and in publications in 2024 and 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.